Press Resease

Leukemia Therapeutics Market - Global Industry Analysis

Leukemia Therapeutics Market - By Leukemia Type (Acute lymphocytic leukemia (ALL), Chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML), By Treatment Type (Targeted drugs & immunotherapy, Chemotherapy, By Molecule Type (Small Molecules, Biologics, By Mode of Administration (Injectable, Oral) - Global Industry Perspective, Comprehensive Analysis and Forecast, 2021-2028

Published Date: 06-Sep-2021 Category: Pharmaceutical Report Format : PDF Pages: 110 Report Code: ZMR-1272 Status : Published

The global Leukemia Therapeutics Market accounted for USD 13.85 Billion in 2020 and is expected to reach USD 24.70 Billion by 2028, growing at a CAGR of 7.5% from 2021 to 2028.

Description

Market Overview

In terms of revenue, the global Leukemia Therapeutics Market accounted for USD 13.85 Billion in 2020 and is expected to reach USD 24.70 Billion by 2028, growing at a CAGR of 7.5% from 2021 to 2028.

Leukemia is also known as blood cancer. There are various categories of blood cells, including red blood cells (RBCs), white blood cells (WBCs), and platelets. Commonly, leukemia refers to cancers of the white blood cells (WBCs). WBCs are an important part of your immune system as they protect your body from invasion by viruses, bacteria, and fungi, as well as from abnormal cells and other foreign substances. In leukemia, the white blood cells don’t function like normal WBCs and can also divide swiftly and eventually crowd out normal cells.

According to the American Cancer Society, in 2019, in the U.S. approximately 61,780 new cases of leukemia were found. There are various types of leukemia such as, leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). Among them acute myeloid leukemia (AML) is considered as one of the most common types of leukemia in adults.

COVID-19 Impact Analysis

COVID-19 is a global public emergency which have led us to serious implications for all the sectors as it have reduced the growth to a significant level. World is still suffering through an unprecedented COVID-19 outbreak posing social, health, and economic emergency. It’s been a year now since the outbreak of COVID-19 hampering the various markets causing the significant loss in the revenue. However, Healthcare sector, research & development activities can be seen to get on track with new inflow of investments.

Owing to the COVID-19 lockdown in the various countries, the demand of the drugs for chronic diseases have raised tremendously. The people having medications for chronic diseases have managed to store the drugs for overall the period of lockdown. However, COVID-19 have positively impact leukemia therapeutics market.

Growth Factors

The global Leukemia Therapeutics Market growth is majorly driven by key factor that include rising prevalence of Leukemia along with geriatric population and increasing awareness. Furthermore, increasing transition from symptom management to slowing the progression of the disease supports the growth of the market. The rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) is also one of the factor responsible for the growth of the market.

Among them acute myeloid leukemia (AML) is considered as one of the most common types of leukemia in adults. According to American Cancer Society, in United States for year 2020, About 60,530 new cases of leukemia of all kinds and About 19,940 new cases of acute myeloid leukemia (AML) were found. Hence, Owing to the presence of the large base of the participants the Leukemia Therapeutics Market is expected to boost the market.

However, the high cost of the drugs used for treatment of leukemia can be a restrain over the forecast period.

Report Scope:

Report Attribute Details
Base Year 2020
Historic Years 2016 - 2020
Forecast Years 2021 - 2028
Segments Covered By Product Type, By Application, and By End Use
Forecast Units Value (USD Billion), and Volume (Units)
Quantitative Units Revenue in USD million/billion and CAGR from 2021 to 2028
Regions Covered North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World
Countries Covered U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others
Number of Companies Covered 10 companies with scope for including additional 15 companies upon request
Report Coverage Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis.
Customization Scope Avail customized purchase options to meet your exact research needs.

Leukemia Type Segment Analysis Preview:

Based on leukemia type the leukemia therapeutics market is segmented into, Acute lymphocytic leukemia (ALL), Chronic lymphocytic leukemia (CLL), Acute myeloid leukemia (AML), Chronic myeloid leukemia (CML). Among all the types of leukemia, acute myeloid leukemia (AML) is considered as one of the most common type. According to American Cancer Society, in United States for year 2020, About 19,940 new cases of acute myeloid leukemia (AML) were found. Hence, owing to the large base of population suffering from leukemia the leukemia therapeutics market is anticipated to grow over the forecast period.

Mode of Administration Segment Analysis Preview:

Based on mode of administration the leukemia therapeutics market is segmented into, Injectable, Oral. Owing to the self-medication possibility and easy to use the oral route of administration is likely to dominate the segment.

Regional Analysis Preview

North America Holds the Largest Share in the leukemia therapeutics market owing to the presence of high incidence rate, and advancements in the treatment of leukemia. According to American Cancer Society estimates, in U.S. for year 2020, 23,100 deaths were caused from leukemia of all kinds. The measurements involve a large percentage of the adult population and they require proper medical treatment to increase their life expectancy. Hence, North America is anticipated to hold the largest share over the forecast period.

Asia pacific is the most promising region and holds significant opportunities in the global Rheumatology Therapeutics Market. The factors the supplements the growth of the market includes huge patient pool, increased RD activities for the development of novel biologics.

Key Market Players & Competitive Landscape

Some of key players in leukemia therapeutics market are,

  1. Novartis
  2. AbbVie
  3. Bristol-Myers Squibb
  4. F. Hoffmann-La Roche
  5. Sanofi
  6. Pfizer
  7. Amgen
  8. Gilead Sciences
  9. Takeda Pharmaceutical
  10. Celgene

The Leukemia Therapeutics Market is segmented as follows:

By Leukemia Type

  • Acute lymphocytic leukemia (ALL)
  • Chronic lymphocytic leukemia (CLL)
  • Acute myeloid leukemia (AML)
  • Chronic myeloid leukemia (CML)

By Treatment Type

  • Targeted drugs & immunotherapy
  • Chemotherapy

By Molecule Type

  • Small Molecules
  • Biologics

By Mode of Administration

  • Injectable
  • Oral

Table Of Content

  • CHAPTER NO. 1: INTRODUCTION
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • CHAPTER NO. 2: EXECUTIVE SUMMARY
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Leukemia Type
        • 2.1.1.2. Market Attractiveness Analysis, By Treatment Type
        • 2.1.1.3. Market Attractiveness Analysis, By Mulecule Type
        • 2.1.1.4. Market Attractiveness Analysis, By Mode of Administration
        • 2.1.1.5. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Leukemia Therapeutics Market, 2016 – 2028 (USD Million)
    • 2.4. Insights from Primary Respondents
  • CHAPTER NO. 3: COVID 19 IMPACT ANALYSIS
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • CHAPTER NO. 4: LEUKEMIA THERAPEUTICS MARKET – BY LEUKEMIA TYPE SEGMENT ANALYSIS
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Leukemia Type, 2020 & 2028
    • 4.2. Acute lymphocytic leukemia (ALL)
      • 4.2.1. Market Size and Forecast, By Region (USD Million)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Chronic lymphocytic leukemia (CLL)
      • 4.3.1. Market Size and Forecast, By Region (USD Million)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Acute myeloid leukemia (AML)
      • 4.4.1. Market Size and Forecast, By Region (USD Million)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.5. Chronic myeloid leukemia (CML)
      • 4.5.1. Market Size and Forecast, By Region (USD Million)
      • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
  • CHAPTER NO. 5: LEUKEMIA THERAPEUTICS MARKET – BY TREATMENT TYPE SEGMENT ANALYSIS
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Treatment Type, 2020 & 2028
    • 5.2. Targeted drugs & immunotherapy
      • 5.2.1. Market Size and Forecast, By Region (USD Million)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Chemotherapy
      • 5.3.1. Market Size and Forecast, By Region (USD Million)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • CHAPTER NO. 6: LEUKEMIA THERAPEUTICS MARKET – BY MulECULE TYPE SEGMENT ANALYSIS
    • 6.1. Overview
      • 6.1.1. Market Revenue Share, By Mulecule Type, 2020 & 2028
    • 6.2. Small Mulecules
      • 6.2.1. Market Size and Forecast, By Region (USD Million)
      • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Biulogics
      • 6.3.1. Market Size and Forecast, By Region (USD Million)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
  • CHAPTER NO. 7: LEUKEMIA THERAPEUTICS MARKET – BY MODE OF ADMINISTRATION SEGMENT ANALYSIS
    • 7.1. Overview
      • 7.1.1. Market Revenue Share, By Mode of Administration, 2020 & 2028
    • 7.2. Injectable
      • 7.2.1. Market Size and Forecast, By Region (USD Million)
      • 7.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 7.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 7.3. Oral
      • 7.3.1. Market Size and Forecast, By Region (USD Million)
      • 7.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 7.3.3. Key Market Trends, Growth Factors, & Opportunities
  • CHAPTER NO. 8: LEUKEMIA THERAPEUTICS MARKET – REGIONAL ANALYSIS
    • 8.1. Overview
      • 8.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 8.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
    • 8.2. North America
      • 8.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 8.2.2. North America Market Revenue, By Leukemia Type, 2016 – 2028
      • 8.2.3. North America Market Revenue, By Treatment Type, 2016 – 2028
      • 8.2.4. North America Market Revenue, By Mulecule Type, 2016 – 2028
      • 8.2.5. North America Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.2.6. U.S.
        • 8.2.6.1. U.S. Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.2.6.2. U.S. Market Revenue, By Treatment Type, 2016 – 2028
        • 8.2.6.3. U.S. Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.2.6.4. U.S. Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.2.7. Canada
        • 8.2.7.1. Canada Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.2.7.2. Canada Market Revenue, By Treatment Type, 2016 – 2028
        • 8.2.7.3. Canada Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.2.7.4. Canada Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.2.8. Mexico
        • 8.2.8.1. Mexico Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.2.8.2. Mexico Market Revenue, By Treatment Type, 2016 – 2028
        • 8.2.8.3. Mexico Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.2.8.4. Mexico Market Revenue, By Mode of Administration, 2016 – 2028
    • 8.3. Europe
      • 8.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 8.3.2. Europe Market Revenue, By Leukemia Type, 2016 – 2028
      • 8.3.3. Europe Market Revenue, By Treatment Type, 2016 – 2028
      • 8.3.4. Europe Market Revenue, By Mulecule Type, 2016 – 2028
      • 8.3.5. Europe Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.3.6. Germany
        • 8.3.6.1. Germany Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.3.6.2. Germany Market Revenue, By Treatment Type, 2016 – 2028
        • 8.3.6.3. Germany Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.3.6.4. Germany Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.3.7. France
        • 8.3.7.1. France Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.3.7.2. France Market Revenue, By Treatment Type, 2016 – 2028
        • 8.3.7.3. France Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.3.7.4. France Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.3.8. U.K.
        • 8.3.8.1. U.K. Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.3.8.2. U.K. Market Revenue, By Treatment Type, 2016 – 2028
        • 8.3.8.3. U.K. Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.3.8.4. U.K. Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.3.9. Italy
        • 8.3.9.1. Italy Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.3.9.2. Italy Market Revenue, By Treatment Type, 2016 – 2028
        • 8.3.9.3. Italy Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.3.9.4. Italy Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.3.10. Spain
        • 8.3.10.1. Spain Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.3.10.2. Spain Market Revenue, By Treatment Type, 2016 – 2028
        • 8.3.10.3. Spain Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.3.10.4. Spain Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.3.11. Rest of Europe
        • 8.3.11.1. Rest of Europe Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.3.11.2. Rest of Europe Market Revenue, By Treatment Type, 2016 – 2028
        • 8.3.11.3. Rest of Europe Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.3.11.4. Rest of Europe Market Revenue, By Mode of Administration, 2016 – 2028
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 8.4.2. Asia Pacific Market Revenue, By Leukemia Type, 2016 – 2028
      • 8.4.3. Asia Pacific Market Revenue, By Treatment Type, 2016 – 2028
      • 8.4.4. Asia Pacific Market Revenue, By Mulecule Type, 2016 – 2028
      • 8.4.5. Asia Pacific Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.4.6. China
        • 8.4.6.1. China Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.4.6.2. China Market Revenue, By Treatment Type, 2016 – 2028
        • 8.4.6.3. China Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.4.6.4. China Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.4.7. Japan
        • 8.4.7.1. Japan Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.4.7.2. Japan Market Revenue, By Treatment Type, 2016 – 2028
        • 8.4.7.3. Japan Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.4.7.4. Japan Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.4.8. India
        • 8.4.8.1. India Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.4.8.2. India Market Revenue, By Treatment Type, 2016 – 2028
        • 8.4.8.3. India Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.4.8.4. India Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.4.9. South Korea
        • 8.4.9.1. South Korea Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.4.9.2. South Korea Market Revenue, By Treatment Type, 2016 – 2028
        • 8.4.9.3. South Korea Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.4.9.4. South Korea Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.4.10. South-East Asia
        • 8.4.10.1. South-East Asia Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.4.10.2. South-East Asia Market Revenue, By Treatment Type, 2016 – 2028
        • 8.4.10.3. South-East Asia Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.4.10.4. South-East Asia Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.4.11. Rest of Asia Pacific
        • 8.4.11.1. Rest of Asia Pacific Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.4.11.2. Rest of Asia Pacific Market Revenue, By Treatment Type, 2016 – 2028
        • 8.4.11.3. Rest of Asia Pacific Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.4.11.4. Rest of Asia Pacific Market Revenue, By Mode of Administration, 2016 – 2028
    • 8.5. Latin America
      • 8.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 8.5.2. Latin America Market Revenue, By Leukemia Type, 2016 – 2028
      • 8.5.3. Latin America Market Revenue, By Treatment Type, 2016 – 2028
      • 8.5.4. Latin America Market Revenue, By Mulecule Type, 2016 – 2028
      • 8.5.5. Latin America Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.5.6. Brazil
        • 8.5.6.1. Brazil Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.5.6.2. Brazil Market Revenue, By Treatment Type, 2016 – 2028
        • 8.5.6.3. Brazil Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.5.6.4. Brazil Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.5.7. Argentina
        • 8.5.7.1. Argentina Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.5.7.2. Argentina Market Revenue, By Treatment Type, 2016 – 2028
        • 8.5.7.3. Argentina Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.5.7.4. Argentina Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.5.8. Rest of Latin America
        • 8.5.8.1. Rest of Latin America Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.5.8.2. Rest of Latin America Market Revenue, By Treatment Type, 2016 – 2028
        • 8.5.8.3. Rest of Latin America Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.5.8.4. Rest of Latin America Market Revenue, By Mode of Administration, 2016 – 2028
    • 8.6. The Middle-East and Africa
      • 8.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 8.6.2. The Middle-East and Africa Market Revenue, By Leukemia Type, 2016 – 2028
      • 8.6.3. The Middle-East and Africa Market Revenue, By Treatment Type, 2016 – 2028
      • 8.6.4. The Middle-East and Africa Market Revenue, By Mulecule Type, 2016 – 2028
      • 8.6.5. The Middle-East and Africa Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.6.6. GCC Countries
        • 8.6.6.1. GCC Countries Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.6.6.2. GCC Countries Market Revenue, By Treatment Type, 2016 – 2028
        • 8.6.6.3. GCC Countries Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.6.6.4. GCC Countries Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.6.7. South Africa
        • 8.6.7.1. South Africa Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.6.7.2. South Africa Market Revenue, By Treatment Type, 2016 – 2028
        • 8.6.7.3. South Africa Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.6.7.4. South Africa Market Revenue, By Mode of Administration, 2016 – 2028
      • 8.6.8. Rest of Middle-East Africa
        • 8.6.8.1. Rest of Middle-East Africa Market Revenue, By Leukemia Type, 2016 – 2028
        • 8.6.8.2. Rest of Middle-East Africa Market Revenue, By Treatment Type, 2016 – 2028
        • 8.6.8.3. Rest of Middle-East Africa Market Revenue, By Mulecule Type, 2016 – 2028
        • 8.6.8.4. Rest of Middle-East Africa Market Revenue, By Mode of Administration, 2016 – 2028
  • CHAPTER NO. 9: LEUKEMIA THERAPEUTICS MARKET – INDUSTRY ANALYSIS
    • 9.1. Introduction
    • 9.2. Market Drivers
      • 9.2.1. Driving Factor 1 Analysis
      • 9.2.2. Driving Factor 2 Analysis
    • 9.3. Market Restraints
      • 9.3.1. Restraining Factor Analysis
    • 9.4. Market Opportunities
      • 9.4.1. Market Opportunity Analysis
    • 9.5. Porter’s Five Forces Analysis
    • 9.6. PEST Analysis
    • 9.7. Regulatory Landscape
    • 9.8. Technology Landscape
    • 9.9. Regional Market Trends
      • 9.9.1. North America
      • 9.9.2. Europe
      • 9.9.3. Asia Pacific
      • 9.9.4. Latin America
      • 9.9.5. The Middle-East and Africa
    • 9.10. Pricing Analysis
    • 9.11. Value Chain Analysis
    • 9.12. Downstream Buyers
    • 9.13. Distributors/Traders List
  • CHAPTER NO. 10: COMPETITIVE LANDSCAPE
    • 10.1. Company Market Share Analysis – 2019
      • 10.1.1. Global Leukemia Therapeutics Market: Company Market Share, 2019
      • 10.1.2. Global Leukemia Therapeutics Market, Company Market Revenue, 2016 – 2019 (USD Million)
      • 10.1.3. Global Leukemia Therapeutics Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 10.1.4. Global Leukemia Therapeutics Market: Radar Determinant Chart, 2019
    • 10.2. Strategic Developments
      • 10.2.1. Acquisitions & Mergers
      • 10.2.2. New Product Launch
      • 10.2.3. Regional Expansion
    • 10.3. Company Strategic Developments – Heat Map Analysis
  • CHAPTER NO. 11: COMPANY PROFILES
    • 11.1. Novartis
      • 11.1.1. Company Overview
      • 11.1.2. Key Executives
      • 11.1.3. Product Portfolio
      • 11.1.4. Financial Overview
      • 11.1.5. Operating Business Segments
      • 11.1.6. Business Performance
      • 11.1.7. Recent Developments
    • 11.2. AbbVie
    • 11.3. Bristul-Myers Squibb
    • 11.4. F. Hoffmann-La Roche
    • 11.5. Sanofi
    • 11.6. Pfizer
    • 11.7. Amgen
    • 11.8. Gilead Sciences
    • 11.9. Takeda Pharmaceutical
    • 11.10. Celgene
  • CHAPTER NO. 12: MARKETING STRATEGY ANALYSIS
    • 12.1. Marketing Channel
    • 12.2. Direct Marketing
    • 12.3. Indirect Marketing
    • 12.4. Marketing Channel Development Trends
    • 12.5. Economic/Pulitical Environmental Change
  • CHAPTER NO. 13: RESEARCH METHODulOGY
    • 13.1. Research Methodology
    • 13.2. Phase I - Secondary Research
    • 13.3. Phase II - Data Modeling
      • 13.3.1. Company Share Analysis Model
      • 13.3.2. Revenue Based Modeling
    • 13.4. Phase III - Primary Research
    • 13.5. Research Limitations
      • 13.5.1. Assumptions

List of Figures 

FIG NO. 1. Market Attractiveness Analysis, By Leukemia Type
FIG NO. 2. Market Attractiveness Analysis, By Treatment Type
FIG NO. 3. Market Attractiveness Analysis, By Molecule Type
FIG NO. 4. Market Attractiveness Analysis, By Mode of Administration
FIG NO. 5. Market Attractiveness Analysis, By Region
FIG NO. 6. Global Leukemia Therapeutics Market Revenue, 2016 – 2028 (USD Million)
FIG NO. 7. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 8. Market Revenue Share, By Leukemia Type, 2020 & 2028
FIG NO. 9. Global Leukemia Therapeutics Market for Acute lymphocytic leukemia (ALL), Revenue (USD Million) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of Leukemia Therapeutics Market for Acute lymphocytic leukemia (ALL), By Country, 2020 & 2028
FIG NO. 11. Global Leukemia Therapeutics Market for Chronic lymphocytic leukemia (CLL), Revenue (USD Million) 2016 – 2028
FIG NO. 12. Comparative Revenue Analysis of Leukemia Therapeutics Market for Chronic lymphocytic leukemia (CLL), By Country, 2020 & 2028
FIG NO. 13. Global Leukemia Therapeutics Market for Acute myeloid leukemia (AML), Revenue (USD Million) 2016 – 2028
FIG NO. 14. Comparative Revenue Analysis of Leukemia Therapeutics Market for Acute myeloid leukemia (AML), By Country, 2020 & 2028
FIG NO. 15. Global Leukemia Therapeutics Market for Chronic myeloid leukemia (CML), Revenue (USD Million) 2016 – 2028
FIG NO. 16. Comparative Revenue Analysis of Leukemia Therapeutics Market for Chronic myeloid leukemia (CML), By Country, 2020 & 2028
FIG NO. 17. Market Revenue Share, By Treatment Type, 2020 & 2028
FIG NO. 18. Global Leukemia Therapeutics Market for Targeted drugs & immunotherapy, Revenue (USD Million) 2016 – 2028
FIG NO. 19. Comparative Revenue Analysis of Leukemia Therapeutics Market for Targeted drugs & immunotherapy, By Country, 2020 & 2028
FIG NO. 20. Global Leukemia Therapeutics Market for Chemotherapy, Revenue (USD Million) 2016 – 2028
FIG NO. 21. Comparative Revenue Analysis of Leukemia Therapeutics Market for Chemotherapy, By Country, 2020 & 2028
FIG NO. 22. Market Revenue Share, By Molecule Type, 2020 & 2028
FIG NO. 23. Global Leukemia Therapeutics Market for Small Molecules, Revenue (USD Million) 2016 – 2028
FIG NO. 24. Comparative Revenue Analysis of Leukemia Therapeutics Market for Small Molecules, By Country, 2020 & 2028
FIG NO. 25. Global Leukemia Therapeutics Market for Biologics, Revenue (USD Million) 2016 – 2028
FIG NO. 26. Comparative Revenue Analysis of Leukemia Therapeutics Market for Biologics, By Country, 2020 & 2028
FIG NO. 27. Market Revenue Share, By Mode of Administration, 2020 & 2028
FIG NO. 28. Global Leukemia Therapeutics Market for Injectable, Revenue (USD Million) 2016 – 2028
FIG NO. 29. Comparative Revenue Analysis of Leukemia Therapeutics Market for Injectable, By Country, 2020 & 2028
FIG NO. 30. Global Leukemia Therapeutics Market for Oral, Revenue (USD Million) 2016 – 2028
FIG NO. 31. Comparative Revenue Analysis of Leukemia Therapeutics Market for Oral, By Country, 2020 & 2028
FIG NO. 32. Global Leukemia Therapeutics Market Revenue Share, By Region, 2020 & 2028
FIG NO. 33. North America Leukemia Therapeutics Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 34. Porter’s Five Forces Analysis for Global Leukemia Therapeutics Market
FIG NO. 35. PEST Analysis for Global Leukemia Therapeutics Market
FIG NO. 36. Pricing Analysis for Global Leukemia Therapeutics Market
FIG NO. 37. Value Chain Analysis for Global Leukemia Therapeutics Market
FIG NO. 38. Company Share Analysis, 2019
FIG NO. 39. Radar Determinant Chart, 2019
FIG NO. 40. Company Strategic Developments – Heat Map Analysis
FIG NO. 41. Novartis Business Segment Revenue Share, 2020 (%)
FIG NO. 42. Novartis Geographical Segment Revenue Share, 2020 (%)
FIG NO. 43. Market Channels
FIG NO. 44. Marketing Channel Development Trend
FIG NO. 45. Growth in World Gross Product, 2008-2018
FIG NO. 46. Research Methodology – Detailed View
FIG NO. 47. Research Methodology


List of Tables 

TABLE NO. 1: Global Leukemia Therapeutics Market: Snapshot
TABLE NO. 2: Quarterly Leukemia Therapeutics Market Revenue by Region, 2020
TABLE NO. 3: Quarterly Leukemia Therapeutics Market Revenue Forecast by Region, 2021
TABLE NO. 4: Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
TABLE NO. 5: Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
TABLE NO. 6: Global Leukemia Therapeutics Market for Acute lymphocytic leukemia (ALL), by Region, 2016 – 2028 (USD Million)
TABLE NO. 7: Global Leukemia Therapeutics Market for Chronic lymphocytic leukemia (CLL), by Region, 2016 – 2028 (USD Million)
TABLE NO. 8: Global Leukemia Therapeutics Market for Acute myeloid leukemia (AML), by Region, 2016 – 2028 (USD Million)
TABLE NO. 9: Global Leukemia Therapeutics Market for Chronic myeloid leukemia (CML), by Region, 2016 – 2028 (USD Million)
TABLE NO. 10: Global Leukemia Therapeutics Market for Targeted drugs & immunotherapy, by Region, 2016 – 2028 (USD Million)
TABLE NO. 11: Global Leukemia Therapeutics Market for Chemotherapy, by Region, 2016 – 2028 (USD Million)
TABLE NO. 12: Global Leukemia Therapeutics Market for Small Molecules, by Region, 2016 – 2028 (USD Million)
TABLE NO. 13: Global Leukemia Therapeutics Market for Biologics, by Region, 2016 – 2028 (USD Million)
TABLE NO. 14: Global Leukemia Therapeutics Market for Injectable, by Region, 2016 – 2028 (USD Million)
TABLE NO. 15: Global Leukemia Therapeutics Market for Oral, by Region, 2016 – 2028 (USD Million)
TABLE NO. 16: Global Leukemia Therapeutics Market Revenue, By Region, 2016 – 2028 (USD Million)
TABLE NO. 17: North America Leukemia Therapeutics Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 18: North America Leukemia Therapeutics Market Revenue, By Leukemia Type, 2016 – 2028 (USD Million)
TABLE NO. 19: North America Leukemia Therapeutics Market Revenue, By Treatment Type, 2016 – 2028 (USD Million)
TABLE NO. 20: North America Leukemia Therapeutics Market Revenue, By Molecule Type, 2016 – 2028 (USD Million)
TABLE NO. 21: North America Leukemia Therapeutics Market Revenue, By Mode of Administration, 2016 – 2028 (USD Million)
TABLE NO. 22: U.S. Leukemia Therapeutics Market Revenue, By Leukemia Type, 2016 – 2028 (USD Million)
TABLE NO. 23: U.S. Leukemia Therapeutics Market Revenue, By Treatment Type, 2016 – 2028 (USD Million)
TABLE NO. 24: U.S. Leukemia Therapeutics Market Revenue, By Molecule Type, 2016 – 2028 (USD Million)
TABLE NO. 25: U.S. Leukemia Therapeutics Market Revenue, By Mode of Administration, 2016 – 2028 (USD Million)
TABLE NO. 26: Canada Leukemia Therapeutics Market Revenue, By Leukemia Type, 2016 – 2028 (USD Million)
TABLE NO. 27: Canada Leukemia Therapeutics Market Revenue, By Treatment Type, 2016 – 2028 (USD Million)
TABLE NO. 28: Canada Leukemia Therapeutics Market Revenue, By Molecule Type, 2016 – 2028 (USD Million)
TABLE NO. 29: Canada Leukemia Therapeutics Market Revenue, By Mode of Administration, 2016 – 2028 (USD Million)
TABLE NO. 30: Mexico Leukemia Therapeutics Market Revenue, By Leukemia Type, 2016 – 2028 (USD Million)
TABLE NO. 31: Mexico Leukemia Therapeutics Market Revenue, By Treatment Type, 2016 – 2028 (USD Million)
TABLE NO. 32: Mexico Leukemia Therapeutics Market Revenue, By Molecule Type, 2016 – 2028 (USD Million)
TABLE NO. 33: Mexico Leukemia Therapeutics Market Revenue, By Mode of Administration, 2016 – 2028 (USD Million)
TABLE NO. 34: Drivers for the Leukemia Therapeutics Market: Impact Analysis
TABLE NO. 35: Restraints for the Leukemia Therapeutics Market: Impact Analysis
TABLE NO. 36: Major Buyers of Leukemia Therapeutics
TABLE NO. 37: Distributors/Traders List of Leukemia Therapeutics
TABLE NO. 38: Global Leukemia Therapeutics Market, Company Market Revenue, 2016 – 2019 (USD Million)
TABLE NO. 39: Global Leukemia Therapeutics Market, Company Y-o-Y Growth, 2017 – 2019 (USD Million)

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Leukemia Therapeutics market. Zion Research has collected and analyzed key data belong to the global Leukemia Therapeutics market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account, while estimating market size. The revenue generated by the leading industry participants in from the sales of Leukemia Therapeutics across the world has been calculated through primary and secondary research.

Zion Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in validation of findings from secondary research and to understand key trends in the Leukemia Therapeutics industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Leukemia Therapeutics market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Leukemia is cancer of the blood cells. Blood cells are red blood cells (RBC or erythrocyte), white blood cells (WBC or leukocyte) and platelets (thrombocytes). Most blood cells are generated in the bone marrow from hematopoietic stem cells (HSCs) and undergo maturation process called hematopoiesis. Hematopoietic stem cells give rise to both myeloid and lymphoid lineage cells and are capable of forming all three types of blood cells. In leukemia, immature blood cells undergo abnormal growth, forming a high number of cancerous cells called blasts. White blood cells are the most common type of blood cell to become cancer. Leukemia can be acute or chronic. Fast-growing cancer which worsens quickly as acute whereas slower-growing cancer that worsens slowly over time is chronic. Mainly there are four types of leukemia as chronic lymphatic leukemia, chronic myeloid leukemia, acute lymphatic leukemia and acute myeloid leukemia.

As per World Cancer Research Fund International, 352 cases of leukemia were diagnosed per 1000 people, in 2012.  As per National Cancer Institute, the numbers of expected new cases of leukemia in the US for 2016 are about 60,000 and about 24,000 estimated deaths. Approximately 1.5 percent of men and women will be diagnosed with leukemia at some point during their lifetime, based on 2011-2013 data. An estimated 1,185,053 people in the US are either living with or are in remission from, leukemia, lymphoma or myeloma. Treatment for leukemia depends on the type of blood cell affected and whether the leukemia is acute or chronic.

Novel drug discovery approaches and the need for early diagnosis along with growing incidence rate of target disease are expected to be the major drivers for the global leukemia therapeutics market. In addition, rising aging population base will surge the drug market worldwide in the coming years. However, the high price of a treatment therapy and lack of early detection techniques and awareness may pose the challenge to leukemia therapeutics market. Government funding and increasing healthcare expenditure across the globe are expected to act an opportunity for leukemia therapeutics market in near future.

Based on the type, leukemia therapeutics market has been segmented into acute leukemia, chronic leukemia, and others. Acute leukemia segment is subdivided into acute lymphatic leukemia and acute myeloid leukemia whereas chronic leukemia is sub-segmented as chronic lymphatic leukemia and chronic myeloid leukemia. The market is segmented into chemotherapy, biological therapy, radiation therapy, targeted therapy and other based on therapy. Based on geography, leukemia therapeutic market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa.

North America is expected to remain the dominant region over the forecast period. High prevalence of target disease in this region and increasing healthcare awareness is expected to boost the market in this region. Europe was the second largest market followed by Asia-Pacific. Asia-Pacific is expected to show fastest growth rate during the forecast period. The Middle East and Africa, and Latin America are also expected to experience noticeable growth in the years to come.

Some of the key players in leukemia therapeutics market include F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc., Genzyme Corporation,  AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The global leukemia therapeutics market was valued at USD 13.85 Billion in 2020.

The global leukemia therapeutics market is expected to reach USD 24.70 Billion by 2028, growing at a CAGR of 7.5% between 2021 to 2028.

Global leukemia therapeutics market, the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) is also one of the factor responsible for the growth of the market.

North America held a substantial share of the leukemia therapeutics market in 2020.

Some of the major companies operating in leukemia therapeutics market are Novartis, AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Sanofi, Pfizer, Amgen, Gilead Sciences, Takeda Pharmaceutical, Celgene.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed